The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Mutational analysis of >14,000 solid tumor NGS tests from community oncology practices: The Sarah Cannon molecular landscape.
 
Andrew McKenzie
No Relationships to Disclose
 
Daniel Schlauch
No Relationships to Disclose
 
Yasha Sharma
Employment - Convergent Dental (I); Sarah Cannon Research Institute
Stock and Other Ownership Interests - Convergent Dental (I)
 
Shaita Picard
Employment - Sarah Cannon Research Institute
Travel, Accommodations, Expenses - Sarah Cannon Research Institute
 
Connor Higgins
Employment - Genospace, LLC; Sarah Cannon Research Institute
Travel, Accommodations, Expenses - Genospace, LLC; Sarah Cannon Research Institute
Other Relationship - Genospace, LLC; HCA Healthcare; Sarah Cannon Research Institute
 
Amanda Misch
Employment - HCA Healthcare
 
Yonghong Xiao
Employment - Genospace, LLC; H3 Biomedicine; Tesaro
Stock and Other Ownership Interests - Tesaro
Patents, Royalties, Other Intellectual Property - I am on a Tesaro patent application that is in progress
 
Rebecca Lachs
Employment - Sarah Cannon Research Institute
Stock and Other Ownership Interests - HCA Healthcare
Travel, Accommodations, Expenses - Sarah Cannon Research Institute
 
Niall OConnor
Employment - IBM (I); IQVIA (I); IQVIA (I); Sarah Cannon Research Institute/Genospace
Leadership - Genospace
Stock and Other Ownership Interests - HCA Healthcare
 
Mick Correll
Employment - Sarah Cannon Research Institute
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
David R. Spigel
Leadership - TriStar Centennial Medical Center
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Evelo Therapeutics (Inst); Foundation Medicine (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Illumina (Inst); Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Precision Oncology (Inst); Takeda (Inst); TRM Oncology (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Aeglea Biotherapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Foundation Medicine (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Pfizer (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; Genzyme; Intuitive Surgical; Lilly; Merck; Pfizer; Purdue Pharma; Spectrum Pharmaceuticals; Sysmex
 
Howard A. Burris
Employment - HCA Healthcare
Leadership - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); FORMA Therapeutics (Inst); Janssen (Inst); MedImmune (Inst); Mersana (Inst); Novartis (Inst); Roche/Genentech (Inst); TG Therapeutics (Inst)
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CicloMed (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Harpoon therapeutics (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jiangsu Hengrui Medicine (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); TG Therapeutics (Inst); Valent Technologies (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - Novartis
 
Suzanne Fields Jones
Consulting or Advisory Role - Clovis Oncology (Inst); Janssen (Inst); Novartis (Inst); Onyx (Inst); Teva (Inst); Vertex (Inst)
 
Holli Hutcheson Dilks
No Relationships to Disclose